Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022

Rhea-AI Summary

Aptose Biosciences (Nasdaq: APTO; TSX: APS) will report its financial results for the quarter ended March 31, 2022, on May 9, 2022, after market close. The company, focused on precision oncology, is developing oral kinase inhibitors for hematologic malignancies, including HM43239 and luxeptinib, which are currently in clinical trials. A conference call is scheduled for the same day at 5:00 PM ET, accessible via toll-free numbers or webcast. Financial statements and management discussions will be available on SEDAR and EDGAR.

Positive

• Aptose's pipeline includes two clinical-stage oral kinase inhibitors for hematologic malignancies.
• The ongoing trials for HM43239 and luxeptinib signal progress in developing innovative oncology treatments.

Negative

• None.

SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended March 31, 2022, on Monday, May 9, 2022 after the close of the market, and provide a corporate update.

Conference Call & Webcast:
Date:	Monday, May 9, 2022
Time:	5:00 PM ET
Dial In - Toll-Free:	866-374-5140
Dial In - International:	404-400-0571
Conference ID:	38238231#
Webcast:	link

The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website here. An archived version of the webcast will be available on the company’s website for 30 days.

The press release, the financial statements and the management’s discussion and analysis for the quarter ended March 31, 2022 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For more information, please visit www.aptose.com.

For further information, please contact:
Aptose Biosciences Inc.	LifeSci Advisors, LLC
Susan Pietropaolo	Dan Ferry, Managing Director
Investor Relations	617-535-7746
201-923-2049	Daniel@LifeSciAdvisors.com
spietropaolo@aptose.com

FAQ

When will Aptose report its Q1 2022 financial results?

Aptose will report its financial results for the quarter ended March 31, 2022, on May 9, 2022.

What time is Aptose's conference call scheduled on May 9, 2022?

The conference call is scheduled for 5:00 PM ET on May 9, 2022.

What is the focus of Aptose Biosciences' drug development?

Aptose specializes in developing precision oncology medications, particularly targeting hematologic malignancies.

Which clinical trials is Aptose currently conducting?

Aptose is conducting trials for HM43239 and luxeptinib, both aimed at treating hematologic malignancies.